Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia

NCT: NCT05452226 · COMPLETED

NCT IDNCT05452226
StatusCOMPLETED
Start Date2022-07-12
Completion2025-12-30

Brief Summary

In older adults hospitalized for acute medical conditions, immobility, clinical treatments, and the illness itself contribute to physical deconditioning and delirium, hospital-acquired impairments that increase risk for long-term physical and mental disability, other morbidities, and death. In patients with acute respiratory failure, hospital-acquired functional impairments persist long after hospitalization, due to limited use to rehabilitative interventions in the inpatient or post-acute settings. Exercise and early mobilization interventions are safe and improve physical and cognitive impairments, but there are critical barriers to their widespread implementation in acute care and home settings, including mobility limitations, reduced cardiopulmonary reserve, limited staff, and costs. Thus, there is an unmet need to develop interventions that can be utilized in both the inpatient and home environments to improve functional recovery in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and community-acquired pneumonia (CAP). This study addresses this clinical need and these barriers and will provide important feasibility and acceptability data regarding the utility of neuromuscular electrical stimulation (NMES) administered to lower extremity musculature across inpatient and post-discharge settings to improve functional and cognitive recovery in older adults hospitalized for AECOPD/CAP. Initial NMES sessions will begin during participants' stay at UVM Medical Center and will continue at home after hospital discharge. Study participants will be issued a portable NMES device to take home and instructed on its use. They will receive guidance and oversight on the use of the NMES device and will be asked to perform NMES treatments 6 days per week for 60 minutes per day for 6 weeks. Data will be collected via activity monitor, participant questionnaires and clinical assessments including strength testing and 6-minute-walk-test.

Frequently Asked Questions

What is Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia?

Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia is a clinical trial registered under NCT05452226. Current status: COMPLETED.

What is the status of NCT05452226?

The current status of NCT05452226 (Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia) is: COMPLETED.

When did Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia start?

Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia started on 2022-07-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.